Oligonucleotide therapeutics: Chemistry, delivery and clinical progress

Future Medicinal Chemistry

Volumn 7, Issue 16, 2015, Pages 2221-2242

  Sharma, Vivek K ^a,b   Watts, Jonathan K ^a,b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; LIPID; LIPOPLEX; MICRORNA; NUCLEASE; NUCLEIC ACID; NUCLEIC ACID BASE; POLYMER; RIBONUCLEASE H; RNA; SUGAR; SUGAR PHOSPHATE; ANTIVIRUS AGENT; OLIGONUCLEOTIDE;

ANTISENSE THERAPY; BINDING AFFINITY; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; DNA CONFORMATION; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GENE SILENCING; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RNA CONFORMATION; CHEMISTRY; DRUG EFFECTS; HEPACIVIRUS;

ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; HEPACIVIRUS; HUMANS; OLIGONUCLEOTIDES;

EID: 84947608741     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.144     Document Type: Review

References (212)

1. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75, 280-284 (1978).
2. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 75, 285-288 (1978).
3. Roehr B. Fomivirsen approved for CMV retinitis. J. Int. Assoc. Physicians AIDS Care 4(10), 14-16 (1998).
4. Jones D. The long march of antisense. Nat. Rev. Drug Discov. 10(6), 401-402 (2011).
5. Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J. Pathol. 226, 365-379 (2012).
6. Hair P, Cameron F, McKeage K. Mipomersen sodium: first global approval. Drugs 73, 487-493 (2013).
7. Sharma VK, Rungta P, Prasad AK. Nucleic acid therapeutics: basic concepts and recent developments. RSC Adv. 4, 16618-16631 (2014).
8. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 5, 123-132 (2006).
9. Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol. 19, 937-954 (2012).
10. Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin. Drug Metab. Toxicol. 9, 169-182 (2013).
11. Shima C, Sakaguchi H, Gomi F et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 86, 372-376 (2008).
12. Anderson KP, Fox MC, Brown-Driver V, Martin MJ, Azad RF. Inhibition of human cytomegalovirus immediateearly gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob. Agents Chemother. 40, 2004-2011 (1996).
13. Apte RS. Pegaptanib sodium for the treatment of agerelated macular degeneration. Expert Opin. Pharmacother. 9, 499-508 (2008).
14. Kanwar JR, Shankaranarayanan JS, Gurudevan S, Kanwar RK. Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discov. Today 19, 1309-1321 (2014).
15. Shima D, Calias P, Adamis AP. WO2005020972A2 (2012).
16. Feingold KR. Does inhibition of apolipoprotein B synthesis produce foie gras? J. Lipid Res. 51, 877-878 (2010).
17. Geary RS, Norris D, Yu R, Bennett CF. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug. Deliv. Rev. 87, 46-51 (2015).
18. Sharma VK, Sharma RK, Singh SK. Antisense oligonucleotides: modifications and clinical trials. Med. Chem. Comm. 5, 1454-1471 (2014).
19. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293 (2010).
20. Alam MR, Dixit V, Kang H et al. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis. Expert Opin. Drug Deliv. 8, 435-449 (2011).
21. Yu B, Zhao X, Lee LJ, Lee RJ. Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 11, 195-203 (2009).
22. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 19, 89-102 (2009).
23. Rautio J, Kumpulainen H, Heimbach T et al. Prodrugs: design and clinical applications. Nat. Rev. Drug Discov. 7, 255-270 (2008).
24. Grijalvo S, Avino A, Eritja R. Oligonucleotide delivery: A patent review (2010-2013). Expert Opin. Ther. Pat. 24, 801-819 (2014).
25. MacLeod AR. Antisense therapies for cancer: bridging the pharmacogenomic divide. Drug Discov, Today Ther. Strateg. 10, e157 (2013).
26. Bedikian AY, Garbe C, Conry R, Lebbe C, Grob JJ. Genasense Melanoma Study Group. Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'. Melanoma Res. 24, 237-243 (2014).
27. Regulus. A single subcutaneous dose of 2mg/kg of RG-101, Regulus' wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122, demonstrates 4.1 log10 mean viral load reduction as monotherapy at day 29 in patients with varied HCV genotypes and treatment history. http://ir.regulusrx.com/releasedetail. cfm?ReleaseID=877462
28. Meade BR, Gogoi K, Hamil AS et al. Efficient delivery of RNAi prodrugs containing reversible chargeneutralizing phosphotriester backbone modifications. Nat. Biotechnol. 32, 1256-1261 (2014).
29. Zamecnik PC, Goodchild J, Taguchi Y, Sarin PS. Inhibition of replication and expression of human T-cell lymphotropic virus type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc. Natl Acad. Sci. USA 83, 4143-4146 (1986).
30. Matsukura M, Shinozuka K, Zon G et al. Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc. Natl Acad. Sci. USA 84, 7706-7710 (1987).
31. Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc. Natl Acad. Sci. USA85, 7079-7083 (1988).
32. Matsukura M, Zon G, Shinozuka K et al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl Acad. Sci. USA 86, 4244-4248 (1989).
33. Mickelfield J. Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr. Med. Chem. 8, 1157-1179 (2001).
34. Jain ML, Bruice PY, Szabó IE, Bruice TC. Incorporation of positively charged linkages into DNA and RNA backbones: A novel strategy for antigene and antisense agents. Chem. Rev. 112, 1284-309 (2012).
35. Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 24, 374-387 (2014).
36. Eckstein F. Phosphorothioate Oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev. 10, 117-121 (2000).
37. Stein CA, Subasinghe C, Shinozuka K, Cohen JS. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16, 3209-3221 (1988).
38. Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin. Drug Met. 5, 381-391 (2009).
39. Pirollo KF, Rait A, Sleer LS, Chang EH. Antisense therapeutics: from theory to clinical practice. Pharmacol. Ther. 99, 55-77 (2003).
40. Lima WF, Prakash TP, Murray HM et al. Single-stranded siRNAs activate RNAi in animals. Cell 150, 883-894 (2012).
41. Hu J, Liu J, Narayanannair KJ et al. Allele-selective inhibition of mutant atrophin-1 expression by duplex and single-stranded RNAs. Biochemistry 53, 4510-4518 (2014).
42. Boczkowska M, Guga P, Stec WJ. Stereodefined phosphorothioate analogues of DNA: relative thermodynamic stability of the model PS-DNA/DNA and PS-DNA/RNA complexes. Biochemistry 41, 12483-12487 (2002).
43. Stec WJ, Cierniewski CS, Okruszek A et al. Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments. Antisense Nucleic Acid Drug Dev. 7, 567-573 (1997).
44. Koziolkiewicz M, Krakowiak A, Kwinkowski M, Boczkowska M, Stec WJ. Stereodifferentiation-The effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. Nucleic Acids Res. 23, 5000-5005 (1995).
45. Gagnon KT, Watts JK. Meeting Report: 10th Annual Meeting of the Oligonucleotide Therapeutics Society. Nucleic Acid Ther. 24, 428-434 (2014).
46. Mergny JL, Lacroix L. Analysis of thermal melting curves. Oligonucleotides 13, 515-537 (2003).
47. LeBlanc DA, Morden KM. Thermodynamic characterization of deoxyribooligonucleotide duplexes containing bulges. Biochemistry 30, 4042-4047 (1991).
48. Puglisi JD, Tinoco I Jr. Absorbance melting curves of RNA. Methods Enzymol. 180, 304-325 (1989).
49. Matveeva OV, Mathews DH, Tsodikov AD et al. Thermodynamic criteria for high hit rate antisense oligonucleotide design. Nucleic Acids Res. 31, 4989-4994 (2003).
50. Crothers DM, Zimm BH. Theory of the melting transition of synthetic polynucleotides: evaluation of the stacking free energy. J. Mol. Biol. 9, 1-9 (1964).
51. Tinoco I Jr, Borer PN, Dengler B et al. Improved estimation of secondary structure in ribonucleic acids. Nat. New Biol. 246, 40-41 (1973).
52. Kierzek E, Mathews DH, Ciesielska A, Turner DH, Kierzek R. Nearest neighbor parameters for Watson-Crick complementary heteroduplexes formed between 2'-O-methyl RNA and RNA oligonucleotides. Nucleic Acids Res. 34, 3609-3614 (2006).
53. Mathews DH. Using OligoWalk to identify efficient siRNA sequences. Methods Mol. Biol. 629, 109-121 (2010).
54. Lu ZJ, Mathews DH. OligoWalk: an online siRNA design tool utilizing hybridization thermodynamics. Nucleic Acids Res. 36(Web Server issue), W104-W108 (2008).
55. Monia BP, Lesnik EA, Gonzalez C et al. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268, 14514-14522 (1993).
56. Stanton R, Sciabola S, Salatto C et al. Chemical modification study of antisense gapmers. Nucleic Acid Ther. 22, 344-359 (2012).
57. Seth PP, Siwkowski A, Allerson CR et al. Short antisense oligonucleotides with novel 2',-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13 (2009).
58. Ferrari N, Seguin R. Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine. PCT/CA2012/000169 (2012).
59. Sipova H, Springer T, Rejman D et al. 5'-O-methylphosphonate nucleic acids-new modified DNAs that increase the Escherichia coli RNase H cleavage rate of hybrid duplexes. Nucleic Acids Res. 42, 5378-5389 (2014).
60. Isobe H, Fujino T, Yamazaki N, Niekowski MG, Nakamura E. Triazole-linked analogue of deoxyribonucleic acid (TLDNA): design, synthesis, and double-strand formation with natural DNA. Org. Lett. 10, 3729-3732 (2008).
61. Varizhuk AM, Kaluzhny DN, Novikov RA et al. Synthesis of triazole-linked oligonucleotides with high affinity to DNA complements and an analysis of their compatibility with biosystems. J. Org. Chem. 78, 5964-5969 (2013).
62. Varizhuk A, Chizhov A, Florentiev V. Synthesis and hybridization data of oligonucleotide analogs with triazole internucleotide linkages, potential antiviral and antitumor agents. Bioorg. Chem. 39, 127-131 (2011).
63. Périgaud C, Gosselin G, Lefebvre I et al. Rational design for cytosolic delivery of nucleoside monphosphates: "SATE" and "DTE" as enzyme-labile transient phosphate protecting groups. Bioorg. Med. Chem. Lett. 3, 2521-2526 (1993).
64. Gao S, Dagnaes-Hansen F, Nielsen EJ et al. The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol. Ther. 17, 1225-1233 (2009).
65. Prakash TP. An overview of sugar-modified oligonucleotides from antisense therapeutics. Chem. Biodivers. 8, 1616-1641 (2011).
66. Wengel J. Synthesis of 3'-C-and 4'-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA). Acc. Chem. Res. 32, 301-306 (1999).
67. Martín-Pintado N, Yahyaee-Anzahaee M, Campos-Olivas R et al. The solution structure of double helical arabino nucleic acids (ANA and 2'F-ANA): effect of arabinoses in duplex-hairpin interconversion. Nucleic Acids Res. 40, 9329-9339 (2012).
68. Bramsen JB, Kjems J. Chemical modification of small interfering RNA. Methods Mol. Biol. 721, 77-103 (2011).
69. Martínez-Montero S, Deleavey GF, Martín-Pintado N, Fakhoury JF, González C, Damha MJ. Locked 2'-deoxy-2',4'-difluororibo modified nucleic acids: thermal stability, structural studies, and siRNA activity. ACS Chem. Biol. doi:10.1021/acschembio.5b00218 (2015) (Epub ahead of print).
70. Whitehead KA, Dahlman JE, Langer RS, Anderson DG. Silencing or stimulation? siRNA delivery and the immune system. Annu. Rev. Chem. Biomol. Eng. 2, 77-96 (2011).
71. Kaur H, Babu BR, Maiti S. Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem. Rev. 107, 4672-4697 (2007).
72. Lindow M, Kauppinen S. Discovering the first microRNAtargeted drug. J. Cell Biol. 199, 407-412 (2012).
73. Obad S, Dos Santos CO, Petri A et al. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43, 371-378 (2011).
74. Wahlestedt C, Salmi P, Good L et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA 97, 5633-5638 (2000).
75. Stein CA, Hansen JB, Lai J et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 38, e3 (2010).
76. Pedersen L, Hagedorn PH, Lindholm MW, Lindow M. A kinetic model explains why shorter and less affine enzymerecruiting oligonucleotides can be more potent. Mol. Ther. Nucleic Acids. 3, e149 (2014).
77. Zhou C, Liu Y, Andaloussi M, Badgujar N, Plashkevych O, Chattopadhyaya J. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and-ENAs leads to significant modulation of antisense properties. J. Org. Chem. 74, 118-134 (2009).
78. Morita K, Hasegawa C, Kaneko M et al. 2'-O,4'-C-ethylenebridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett. 12, 73-76 (2002).
79. Rahman SMA, Seki S, Obika S, Yoshikawa H, Miyashita K, Imanishi T. Design, synthesis and properties of 2',4'-BNA(NC): A bridged nucleic acid analogue. J. Am. Chem. Soc. 130, 4886-4896 (2008).
80. Giannaris P, Damha MJ. Hybridization properties of oligoarabinonucleotides. Can. J. Chem. 72, 909-918 (1994).
81. Noronha AM, Wilds CJ, Lok C-N et al. Synthesis and biophysical properties of arabinonucleic acids (ANA): circular dichroic spectra, melting temperature, and ribonuclease H susceptibility of ANA RNA hybrid duplexes. Biochemistry 39, 7050-7062 (2000).
82. Lima WF, Nichols JG, Wu H et al. Structural requirements at the catalytic site of the heteroduplex substrate for human RNase H1 catalysis. J. Biol. Chem. 279, 36317-36326 (2004).
83. Watts JK, Damha MJ. 2'F-arabinonucleic acids (2'F-ANA)-history, properties, and new frontiers. Can. J. Chem. 86, 641-656 (2008).
84. Wilds CJ, Damha MJ. 2'-deoxy-2'-fluoro-β-Darabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. Nucleic Acids Res. 28, 3625-3635 (2000).
85. Ferrari N, Bergeron D, Tedeschi a-L et al. Characterization of antisense oligonucleotides comprising 2'-deoxy-2'-fluorobeta-D-arabinonucleic acid (FANA): specificity, potency, and duration of activity. Ann. NY Acad. Sci. 1082, 91-102 (2006).
86. Martínez-Montero S, Deleavey GF, Dierker-Viik A et al. Synthesis and properties of 2'-deoxy-2',4'-difluoroarabinosemodified nucleic acids. J. Org. Chem. 80, 3083-3091 (2015).
87. Sørensen MD, Kværnø L, Bryld T et al. Alpha-L-riboconfigured locked nucleic acid (alpha-L-LNA): synthesis and properties J. Am. Chem. Soc. 124, 2164-2176 (2002).
88. Rajwanshi VK, Hakansson AE, Sorensen MD et al. The eight stereoisomers of LNA (locked nucleic acid): A remarkable family of strong RNA binding molecules. Angew. Chem. Int. Ed. Engl. 39, 1656-1659 (2000).
89. Nielsen JT, Stein PC, Petersen M. NMR structure of an α-L-LNA:RNA hybrid: structural implications for RNase H recognition. Nucleic Acids Res. 31, 5858-5867 (2003).
90. Frieden M, Christensen SM, Mikkelsen ND et al. Expanding the design horizon of antisense oligonucleotides with alpha-l-LNA. Nucleic Acids Res. 31, 6365-6372 (2003).
91. Fluiter K, Frieden M, Vreijling J et al. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. Chembiochem. 6, 1104-1109 (2005).
92. Seth PP, Jazayeri A, Yu J, Allerson CR, Bhat B, Swayze EE. Structure activity relationships of α-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol. Ther. Nucleic Acids 18, e47 (2012).
93. Declercq R, Van Aerschot A, Read RJ, Herdewijn P, van Meervelt L. Crystal structure of double helical hexitol nucleic acids. J. Am. Chem. Soc. 124(6), 928-933 (2002).
94. Egli M, Pallan PS, Allerson CR et al. Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3'-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. J. Am. Chem. Soc. 133, 16642-16649 (2011).
95. Van Aerschot A, Meldgaard M, Schepers G et al. Improved hybridisation potential of oligonucleotides comprising O-methylated anhydrohexitol nucleoside congeners. Nucleic Acids Res. 29, 4187-4194 (2001).
96. Verbeure B, Lescrinier E, Wang J, Herdewijn P. RNase H mediated cleavage of RNA by cyclohexene nucleic acid (CeNA). Nucleic Acids Res. 29, 4941-4947 (2001).
97. Wang J, Verbeure B, Luyten I et al. Cyclohexene nucleic acids (CeNA): serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA. J. Am. Chem. Soc. 122, 8595-8602 (2000).
98. Sabatino D, Damha MJ. Oxepane nucleic acids: synthesis, characterization, and properties of oligonucleotides bearing a seven-membered carbohydrate ring. J. Am. Chem. Soc. 129, 8259-8270 (2007).
99. Iversen PL. Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. 3, 235-238 (2001).
100. Mendell JR, Rodino-Klapac LR, Sahenk Z et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74, 637-647 (2013).
101. Iversen PL, Warren TK, Wells JB et al. Discovery and early development of AVI-7537 and AVI-7288 for the treatment of Ebola virus and Marburg virus infections. Viruses 4, 2806-2830 (2012).
102. Sarepta Therapeutics. www.sarepta.com/pipeline/avi-7100-influenza
103. Nulf CJ, Corey D. Intracellular inhibition of hepatitis C virus (HCV) internal ribosomal entry site (IRES)-dependent translation by peptide nucleic acids (PNAs) and locked nucleic acids (LNAs). Nucleic Acids Res. 32, 3792-3798 (2004).
104. Sazani P, Gemignani F, Kang SH et al. Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228-1233 (2002).
105. Siwkowski AM, Malik L, Esau CC et al. Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing. Nucleic Acids Res. 32, 2695-2706 (2004).
106. Abes S, Turner JJ, Ivanova GD et al. Efficient splicing correction by PNA conjugation to an R6-penetratin delivery peptide. Nucleic Acids Res. 35, 4495-4502 (2002).
107. He G, Rapireddy S, Bahal R, Sahu B, Ly DH. Strand invasion of extended, mixed-sequence B-DNA by gammaPNAs. J. Am. Chem. Soc. 131, 12088-12090 (2009).
108. Englund EA, Appella DH. Gamma-substituted peptide nucleic acids constructed from L-lysine are a versatile scaffold for multifunctional display. Angew. Chem. Int. Edit. Engl. 46, 1414-1418 (2007).
109. Herdewijn P. Heterocyclic modifications of oligonucleotide and antisense technology. Antisense Nucleic Acid Drug Dev. 10, 297-310 (2000).
110. Peacock H, Kannan A, Beal PA, Burrows CJ. Chemical modification of siRNA bases to probe and enhance RNA interference. J. Org. Chem. 76, 7295-7300 (2011).
111. Verma S, Eckstein F. Modified oligonucleotides: synthesis and strategy for users. Annu. Rev. Biochem. 67, 99-134 (1998).
112. Freier SM, Altmann KH. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemicallymodified DNA:RNA duplexes. Nucleic Acids Res. 25, 4429-4443 (1997).
113. Takeda K, Akira S. Toll-like receptors in innate immunity. Int. Immunol. 17, 1-14 (2005).
114. Dalpke A, Frank J, Peter M, Heeg K. Activation of toll-like receptor 9 by DNA from different bacterial species. Infect. Immun. 74, 940-946 (2006).
115. Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292, 468-479 (2000).
116. Sagi J, Szemzö A, Otvös L, Vorlickova M, Kypr J. Destabilization of the duplex and the high-salt Z-form of poly(dG-methyl5dC) by substitution of ethyl for the 5-methyl group. Int. J. Biol. Macromol. 13, 329-336 (1991).
117. Froehler BC, Wadwani S, Terhorst TJ, Gerrard SR. Oligodeoxynucleotides containing C-5 propyne analogs of 2'-deoxyuridine and 2'-deoxycytidine. Tetrahedron Lett. 33, 5307-5310 (1992).
118. Wagner RW, Matteucci MD, Lewi JG, Gutierrez AJ, Moulds C, Froehler BC. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science 260, 1510-1513 (1993).
119. Moulds C, Lewis JG, Froehler BC et al. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry 34, 5044-5053 (1995).
120. Shen L, Siwkowski A, Wancewicz EV et al. Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo. Antisense Nucleic Acid Drug Dev. 13, 129-142 (2003).
121. Kumar P, østergaard ME, Baral B et al. Synthesis and biophysical properties of C5-functionalized LNA (locked nucleic acid). J. Org. Chem. 79, 5047-5061 (2014).
122. Morihiro K, Hasegawa O, Mori S, Tsunoda S, Obika S. C5-azobenzene-functionalized locked nucleic acid uridine: isomerization properties, hybridization ability, and enzymatic stability. Org. Biomol. Chem. 13, 5209-5214 (2015).
123. Guenther DC, Kumar P, Anderson BA, Hrdlicka PJ. C5-amino acid functionalized LNA: positively poised for antisense applications. Chem. Commun. (Camb.) 50, 9007-9009 (2014).
124. Kaura M, Guenther DC, Hrdlicka PJ. Carbohydratefunctionalized locked nucleic acids: oligonucleotides with extraordinary binding affinity, target specificity, and enzymatic stability. Org. Lett. 16, 3308-3311 (2014).
125. Flanagan WM, Wagner RW, Grant D, Lin KY, Matteucci MD. Cellular penetration and antisense activity by a phenoxazinesubstituted heptanucleotide. Nat. Biotechnol. 17, 48-52 (1999).
126. Lin K-Y, Matteucci MD. A cytosine analog capable of clamplike binding to a guanine in helical nucleic acids. J. Am. Chem. Soc. 120, 8531-8532 (1998).
127. Wilds CJ, Maier MA, Tereshko V, Manoharan M, Egli M. Direct observation of a cytosine analogue that forms five hydrogen bonds to guanosine: guanidino G-clamp. Angew. Chem. Int. Ed. Engl. 41, 115-117 (2002).
128. Wilds CJ, Maier MA, Manoharan M, Egli M. Structural basis for recognition of guanosine by a synthetic tricyclic cytosine analogue: guanidinium G-clamp. Helv. Chim. Acta 86, 966-978 (2003).
129. Gryaznov SM, Schultz RG. Stabilization of DNA:DNA and DNA:RNA duplex by substitution of 2-deoxyadenosine with 2-deoxy-2-aminoadenosine. Tetrahedron Lett. 36, 2489-2492 (1994).
130. Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr. Drug Discov. Technol. 8, 207-227 (2011).
131. Ballarín-González B, Howard KA. Polycation-based nanoparticle delivery of RNAi therapeutics: adverse effects and solutions. Adv. Drug Deliv. Rev. 64, 1717-1729 (2012).
132. Kichler A, Zauner W, Ogris M, Wagner E. Influence of the DNA complexation medium on the transfection efficiency of lipospermine/DNA particles. Gene Ther. 5, 855-860 (1998).
133. Dalby B, Cates S, Harris A et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and highthroughput applications. Methods 33, 95-103 (2004).
134. Draghici B, Ilies MA. Synthetic nucleic acid delivery systems: present and perspectives. J. Med. Chem. 58, 4091-4130 (2015).
135. Shim G. Application of cationic liposomes for delivery of nucleic acids Asian J. Pharm. Sci. 8, 72-80 (2013).
136. Ma B, Zhang S, Jiang H, Zhao B, Lv H. Lipoplex morphologies and their influences on transfection efficiency in gene delivery. J. Control Release 123, 184-194 (2007).
137. Rädler JO, Koltover I, Salditt T, Safinya CR. Structure of DNa-cationic liposome complexes: DNA intercalation in multilamellar membranes in distinct interhelical packing regimes. Science 275, 810-814 (1997).
138. Koltover I, Salditt T, Rädler JO, Safinya CR. An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science 281, 78-81 (1998).
139. Leal C, Bouxsein NF, Ewert KK, Safinya CR. Highly efficient gene silencing activity of siRNA embedded in a nanostructured gyroid cubic lipid matrix. J. Am. Chem. Soc. 132, 16841-16847 (2010).
140. Leal C, Ewert KK, Shirazi RS, Bouxsein NF, Safinya CR. Nanogyroids incorporating multivalent lipids: enhanced membrane charge density and pore forming ability for gene silencing. Langmuir 27, 7691-7697 (2011).
141. Ewert K, Ahmad A, Evans HM, Schmidt HW, Safinya CR. Efficient synthesis and cell-transfection properties of a new multivalent cationic lipid for nonviral gene delivery. J. Med. Chem. 45, 5023-5029 (2002).
142. Lin AJ, Slack NL, Ahmad A, George CX, Samuel CE, Safinya CR. Three-dimensional imaging of lipid gene-carriers: membrane charge density controls universal transfection behavior in lamellar cationic liposome-DNA complexes. Biophys. J. 84, 3307-3316 (2003).
143. Avanti® Polar Lipids, Inc. www.avantilipids.com/index.php?option=com-content&view =article&id=2422&Itemid=521&catnumber=890000
144. Aliabadi HM, Landry B, Sun C, Tang T, Uludaʇ H. Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials 33, 2546-2569 (2012).
145. Daka A, Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. 64, 1508-1521 (2012).
146. Mui BL, Tam YK, Jayaraman M et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol. Ther. Nucleic Acids 2, e139 (2013).
147. Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E. PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6, 595-605 (1999).
148. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Release 65, 271-284 (2000).
149. Morrissey DV, Lockridge JA, Shaw L et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007 (2005).
150. Zimmermann TS, Lee AC, Akinc A et al. RNAi-mediated gene silencing in non-human primates. Nature 441, 111-114 (2006).
151. Semple SC, Akinc A, Chen J et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172-176 (2010).
152. Geall AJ, Verma A, Otten GR et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604-14609 (2012).
153. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNabased therapeutics. Adv. Drug Deliv. Rev. 87, 108-119 (2015).
154. Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J. Control. Release 126, 187-204 (2008).
155. Niu Y, Sun L, Crooks RM. Determination of the intrinsic proton binding constants for poly(amidoamine) dendrimers via potentiometric pH titration. Macromolecules 36, 5725-5731 (2003).
156. Liang W, Lam JKW. Endosomal escape pathways for nonviral nucleic acid delivery systems. In: Molecular Regulation of Endocytosis. Ceresa B (Ed.). InTech, Croatia, 421-467 (2012).
157. Yessine M-A, Meier C, Petereit H-U, Leroux J-C. On the role of methacrylic acid copolymers in the intracellular delivery of antisense oligonucleotides. Eur. J. Pharm. Biopharm. 63, 1-10 (2006).
158. Convertine AJ, Diab C, Prieve M et al. pHresponsive polymeric micelle carriers for siRNA drugs. Biomacromolecules 11, 2904-2911 (2011).
159. Kim SH, Jeong JH, Mok H, Lee SH, Kim SW, Park TG. Folate receptor targeted delivery of polyelectrolyte complex micelles prepared from ODN-PEG-folate conjugate and cationic lipids. Biotechnol. Prog. 23, 232-237 (2007).
160. Palanca-Wessels MC, Convertine AJ, Cutler-Strom R et al. Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. Mol. Ther. 19, 1529-1537 (2011).
161. Oishi M, Nagasaki Y, Itaka K, Nishiyama N, Kataoka K. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile β-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving enhanced gene silencing in hepatoma cells. J. Am. Chem. Soc. 127, 1624-1625 (2005).
162. Sethuraman V, Lee M, Bae Y. A biodegradable pH-sensitive micelle system for targeting acidic solid tumors. Pharm. Res. 25, 657-666 (2008).
163. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv. 3, 311-324 (2006).
164. Petrova NS, Chernikov IV, Meschaninova MI et al. Carrierfree cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res. 40, 2330-2344 (2012).
165. AVI Biopharma, Inc. WO2012150960 A1 (2012).
166. Zhu H, Li J, Zhang XB, Ye M, Tan W. Nucleic acid aptamermediated drug delivery for targeted cancer therapy. Chem Med Chem. 10, 39-45 (2015).
167. Ristau BT, O'Keefe DS, Bacich DJ. The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol. Oncol. 32, 272-279 (2014).
168. McNamara JO 2nd, Andrechek EO, Wang Y et al. Cell typespecific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015 (2006).
169. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 34, e73 (2006).
170. Zhou J, Swiderski P, Li H et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 37, 3094-3109 (2009).
171. Dassie JP, Liu XY, Thomas GS et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMa-expressing tumors. Nat. Biotech. 27, 839-846 (2009).
172. Grewal PK. The Ashwell-Morell receptor. Methods Enzymol. 479, 223-241 (2010).
173. Nair JK, Willoughby JLS, Chan A et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958-16961 (2014).
174. Rajeev KG, Nair JK, Jayaraman M et al. Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem 16, 903-908 (2015).
175. Matsuda S, Keiser K, Nair JK et al. siRNA conjugates carrying sequentially assembled trivalent nacetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10, 1181-1187 (2015).
176. Prakash TP, Graham MJ, Yu J et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796-8807 (2014).
177. østergaard ME, Yu J, Kinberger GA et al. Efficient synthesis and biological evaluation of 5'-GalNAc conjugated antisense oligonucleotides. Bioconjug. Chem. 26(8), 1451-1455 (2015).
178. Patwa A, Gissot A, Bestel I, Barthelemy P. Hybrid lipid oligonucleotide conjugates: synthesis, self-assemblies and biomedical applications. Chem. Soc. Rev. 40, 5844-5854 (2011).
179. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 14, 4975-4977 (2004).
180. Sylentis SAU. Sphingosine-bound siRNA. US2012142765 A1 (2012).
181. Wolfrum C, Shi S, Jayaprakash KN et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149-1157 (2007).
182. Trajkovski M, Hausser J, Soutschek J et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474, 649-653 (2011).
183. Nishina K, Unno T, Uno Y et al. Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol. Mol. Ther. 16, 734-740 (2008).
184. Nishina T, Numata J, Nishina K et al. Chimeric antisense oligonucleotide conjugated to α-tocopherol. Mol. Ther. Nucleic Acids. 4, e220 (2015).
185. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157, 195-206 (2009).
186. Lundberg P, El-Andaloussi S, Sutlu T, Johansson H, Langel U. Delivery of short interfering RNA using endosomolytic cellpenetrating peptides. FASEB J. 21, 2664-2671 (2007).
187. Fei L, Ren L, Zaro JL, Shen W-C. The influence of net charge and charge distribution on cellular uptake and cytosolic localization of arginine-rich peptides. J. Drug Target 19, 675-680 (2011).
188. Lebleu B, Moulton HM et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv. Drug Deliv. Rev. 60, 517-529 (2008).
189. Goyenvalle A, Babbs A, Powell D et al. Prevention of dystrophic pathology in severely affected dystrophin/utrophindeficient mice by morpholino-oligomer-mediated exonskipping. Mol. Ther. 18, 198-205 (2009).
190. Koppelhus U, Shiraishi T, Zachar V, Pankratova S, Nielsen PE. Improved cellular activity of antisense peptide nucleic acids by conjugation to a cationic peptide-lipid (CatLip) domain. Bioconjugate Chem. 19, 1526-1534 (2008).
191. Poillot C, Bichraoui H, Tisseyre C et al. Small efficient cellpenetrating peptides derived from scorpion toxin maurocalcine. J. Biol. Chem. 287, 17331-17342 (2012).
192. Betts C, Saleh AF, Arzumanov AA et al. Pip6-PMO, a new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment. Mol. Ther. Nucleic Acids 1, e38 (2012).
193. Mirkin CA, Letsinger RL, Mucic RC, Storhoff JJ. A DNAbased method for rationally assembling nanoparticles into macroscopic materials. Nature 382, 607-609 (1996).
194. Rosi NL, Giljohann DA, Thaxton CS, Lytton-Jean AK, Han MS, Mirkin CA. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312, 1027-1030 (2006).
195. Seferos DS, Prigodich AE, Giljohann DA, Patel PC, Mirkin CA. Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. Nano Lett. 9, 308-311 (2009).
196. Lytton-Jean AK, Langer R, Anderson DG. Five years of siRNA delivery: spotlight on gold nanoparticles. Small 7, 1932-1937 (2011).
197. Giljohann DA, Seferos DS, Patel PC, Millstone JE, Rosi NL, Mirkin CA. Oligonucleotide loading determines cellular uptake of DNa-modified gold nanoparticles. Nano Lett. 7, 3818-3821 (2007).
198. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA. Gene regulation with polyvalent siRNa-nanoparticle conjugates. J. Am. Chem. Soc. 131, 2072-2073 (2009).
199. Giljohann DA, Seferos DS, Daniel WL, Massich MD, Patel PC, Mirkin CA. Gold nanoparticles for biology and medicine. Angew. Chem. Int. Ed. Engl. 49, 3280-3294 (2010).
200. Patel PC, Giljohann DA, Daniel WL, Zheng D, Prigodich AE, Mirkin CA. Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles. Bioconjug. Chem. 21, 2250-2256 (2010).
201. Choi CH, Hao L, Narayan SP, Auyeung E, Mirkin CA. Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates. Proc. Natl Acad. Sci. USA 110, 7625-7630 (2013).
202. Zhang K, Hao L, Hurst SJ, Mirkin CA. Antibody-linked spherical nucleic acids for cellular targeting. J. Am. Chem. Soc. 134, 16488-16491 (2012).
203. Lee JS, Lytton-Jean AK, Hurst SJ, Mirkin CA. Silver nanoparticle-oligonucleotide conjugates based on DNA with triple cyclic disulfide moieties. Nano Lett. 7, 2112-2115 (2007).
204. Hilliard LR, Zhao XJ, Tan WH. Immobilization of oligonucleotides onto silica nanoparticles for DNA hybridization studies. Anal. Chim. Acta 470, 51-56 (2002).
205. Cutler JI, Zheng D, Xu X, Giljohann DA, Mirkin CA. Polyvalent oligonucleotide iron oxide nanoparticle "click" conjugates. Nano Lett. 10, 1477-1480 (2010).
206. Medintz IL, Berti L, Pons T et al. A reactive peptidic linker for self-assembling hybrid quantum dot-DNA bioconjugates. Nano Lett. 7, 1741-1748 (2007).
207. Williams SC. Spherical nucleic acids: A whole new ball game. Proc. Natl Acad. Sci. USA 110, 13231-13233 (2013).
208. Banga RJ, Chernyak N, Narayan SP, Nguyen ST, Mirkin CA. Liposomal spherical nucleic acids. J. Am. Chem. Soc. 136, 9866-9869 (2014).
209. Radovic-Moreno AF, Chernyak N, Mader CC et al. Immunomodulatory spherical nucleic acids. Proc. Natl Acad. Sci. USA 112, 3892-3897 (2015).
210. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816-821 (2012).
211. O'Connell MR, Oakes BL, Sternberg SH, East-Seletsky A, Kaplan M, Doudna JA. Programmable RNA recognition and cleavage by CRISPR/Cas9. Nature 516, 263-266 (2014).
212. Barrangou R, Birmingham A, Wiemann S, Beijersbergen RL, Hornung V, Smith AV. Advances in CRISPR-Cas9 genome engineering: lessons learned from RNA interference. Nucleic Acids Res. 43, 3407-3419 (2015).